Using the FastWire System to treat blocked arteries in the legs
Official title: A Pivotal, Single-arm, Multi-centre, Prospective Clinical Investigation to Assess the Efficacy and Safety of the FastWire REvascularisation of Extremities, (For LOWer Limbs) (FREEFLOW).
Run by Versono Medical Ltd · NCT06492733 · Data updated 2026-11-12
This study is testing a new tool called the FastWire System to see if it can help people with blocked leg arteries improve their blood flow and overall health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 65 (estimated) |
| Sponsor | Versono Medical Ltd Industry-sponsored |
| Locations | 6 sites (Wilmington, Delaware and 5 other locations) |
| Status | Recruiting |
| Started | November 5, 2024 |
| Main results expected | November 2026 |
| Study ends | November 2026 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT06492733 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 85 with chronic total occlusions in their lower limb arteries causing severe claudication or critical limb threat.
✕Probably not a fit
Patients with non-occlusive arterial disease or those outside the specified age range may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and effectiveness of the FastWire System for treating chronic total occlusions (CTOs) in the arteries of the lower limbs. It is a single-arm, multi-center investigation involving up to 65 patients who have significant arterial blockages causing ischemia. The FastWire System aims to facilitate the placement of guidewires or treatment devices beyond these blockages, potentially improving blood flow and patient outcomes.
Why it matters
Potential benefit: If successful, this could significantly improve blood flow and quality of life for patients with severe leg ischemia.
How similar studies have gone: Other studies using similar interventional approaches have shown promise, but the FastWire System represents a novel application in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
General Inclusion Criteria: Subjects who meet all the following criteria are eligible for this clinical investigation: 1. The patient signed and dated an Informed Consent Form. 2. Aged between 18 years and 85 years (inclusive). 3. Severe claudication assessed as Rutherford category 3 or CLTI assessed as Rutherford category 4 or 5 LEAD. Angiographic Inclusion Criteria Unless otherwise specified, the Investigator performing the procedure bases angiographic inclusion on the visual determination of qualification imaging taken at the time of the procedure. Subject must meet ALL the following angiographic inclusion criteria: 1. Angiographic confirmation at the time of the procedure of a de novo CTO below the origin of the superficial femoral artery (SFA) including above the knee or below the knee. (Note: Multilevel CTOs are included as long as the total length from the beginning of the most proximal total occlusion to the end of the most distal total occlusion is less than 40 cm.) 2. 100% stenosis by a visual estimate of angiography at the time of procedure. 3. For below-the-knee CTOs, the target limb shall have at least one patent (\<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at the time of the procedure. Exclusion Criteria: Subjects who meet any of the following criteria are not eligible for this clinical investigation: 1. Life expectancy of less than 12 months. 2. Females who are pregnant or lactating (urine test for women of childbearing age). 3. Myocardial infarction or stroke in two months prior to the index procedure. 4. Known, unstable coronary artery disease or other, uncontrolled comorbidity. 5. Any known haemorrhagic or coagulation deficiency. 6. Known sensitivity to nickel, titanium, or their alloys. 7. Evidence of active infection, including but not limited to the target limb. 8. Current use of cocaine or other substances of abuse. 9. Patients who have received any thrombolytic therapy in the last two weeks. 10. History of severe allergy or contraindication, to contrast medium or other medications used during or after endovascular therapy. 11. Subject participating in another study involving an investigational drug or device. 12. Patient has surgery or vascular intervention planned within 30 days of the index procedure. 13. Patient has had a previous peripheral bypass that includes the target vessel. 14. Patient has had a previous intervention in the target CTO (angioplasty, stenting) including previous attempt at time of index procedure. 15. Patient tests positive for coronavirus disease (COVID-2019), as per site standard practice. 16. Estimated Glomerular Filtration Rate (eGFR) of less than 30 ml/min or creatine level \>2.5mg/ml. 17. Platelet count \< 50,000/μL. Angiographic Exclusion Criteria Unless otherwise specified, the Investigator performing the procedure bases angiographic exclusion on a visual determination of qualification imaging taken at the time of the procedure. Subject is excluded if ANY of the following angiographic exclusion criteria is met: 1. For below-the-knee CTOs, a target limb without at least one patent (\<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at the time of the procedure. 2. Has an acute or sub-acute intraluminal thrombus within the target vessel. 3. Aneurysm distal to puncture access site at least twice the reference vessel diameter, located in the index vessel, abdominal aorta, iliac, or popliteal. 4. Has perforation, dissection, or other injury of the access site or index vessel requiring stenting or surgical intervention prior to attempting crossing of the target lesion with the FastWire System.
Where it's running
-
EndoVascular Consultants
Wilmington, Delaware, United States Recruiting -
Vascular & Embolization Specialists
Cocoa, Florida, United States Recruiting -
Vascular Institute of the Midwest
Davenport, Iowa, United States Recruiting -
Cardiovascular Institute of the South-ASC
Gray, Louisiana, United States Recruiting -
Dearborn Cardiology
Dearborn, Michigan, United States Recruiting -
Vascular Institute of Chattanooga
Chattanooga, Tennessee, United States Recruiting
Study contacts
- Study coordinator: Hugh O'Donoghue Chief Technology Officer
- Email: hugh.odonoghue@versono.life
- Phone: 212-252-2059
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using a new guidewire system to treat blocked coronary arteries
This study is testing a new guidewire system to see if it can help doctors treat blocked coronary arteries in patients who have had these blockages for over three months.
-
Comparing heart procedures and medication for blocked coronary arteries
This study is testing if a heart procedure called PCI can help people with completely blocked coronary arteries feel better and have improved heart function compared to just using medication.
-
Comparing two approaches for treating blocked coronary arteries
This study is testing two different methods for treating blocked coronary arteries to see which one works better and is safer for patients with chronic total occlusions.
-
Comparing PCI and medical therapy for chronic total occlusion in heart disease
This study is testing whether a new heart procedure using special stents can help people with blocked arteries feel better and have fewer heart problems compared to just taking medication.
-
Registry for treating chronic total occlusion of coronary arteries in Japan
This study is gathering information from patients in Japan who have had a specific heart procedure to treat blocked arteries, to see how to improve treatment for these cases.
-
Using a drug-coated balloon for treating blocked coronary arteries
This study is testing whether a drug-coated balloon can safely help people with blocked coronary arteries feel better during a heart procedure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.